 |
> 1998 Publications
1.
Reference Ranges for Serum Prostate Specific Antigen
(PSA) in Black and White Men Without Cancer.
Weinrich MC, Jacobsen S, Weinrich SP, Moul JW, Oesterling JE,
Jacobson D, Wise R:
Urology, 52:967-973, 1998. |
2.
Use of Prostate Specific Antigen in Black Men: Age-Adjusted
Reference Ranges for Maximal Cancer Detection.
Moul JW:
J Nat Med Assoc., 90(11-suppl.): 1-2, 1998. |
3.
Treatment Options for Prostate Cancer: Part 1 - Stage,
Grade, PSA, and Changes in the 1990's.
Moul JW:
Am J Manage Care, 4:1031-1036, 1998. |
4. Treatment Options for Prostate Cancer: Part 2 - Early
and Late Stage and Hormone Refractory Disease.
Moul JW:
Am J Manage Care. 4:1171-1180, 1998. |
5. Prostate cancer in African-American men.
Moul JW:
Prostate Cancer and Prost. Dis. 1:109-118, 1998. |
6.
Pelvic Muscle Rehabilitation in Males Following Prostatectomy.
Moul JW:
Urologic Nursing, 18(4): 296-301, 1998. |
7.
Curability of Prostate Cancer in African Americans:
Implications for Neoadjuvant/Adjuvant Hormone Therapy.
Moul JW:
Mol. Urol., 2:209-213, 1998. |
8.
Contemporary hormonal management of advanced prostate
cancer.
Moul JW:
Oncology 12:499-505, 1998. |
9.
Preoperative and operative factors to predict incontinence,
impotence and stricture after radical prostatectomy.
Moul JW, Mooneyhan RM, Kao TC, McLeod DG, Cruess DF:
Prost. Can. Prost Dis., 5:242-249, 1998. |
10.
Metastatic Bone Pain Associated with Prostate Cancer.
Moul JW, Lipo DR:
Home Hlth Care Consult. 5:2-12, 1998. |
11.
The contemporary value of pretreatment prostate acid phosphatase
(PAP) to predict pathologic stage and recurrence in radical
prostatectomy patients.
Moul JW, Connelly RR, Perahia B, McLeod DG:
J Urol, 159:935-40, 1998. |
12.
Perineal seeding of prostate cancer as the only evidence
of recurrence 14 years after needle biopsy and radical prostatectomy
molecular correlation.
Moul JW, Bauer JJ, Srivastava S, Colon E, Sesterhenn IA, Ho
CK, McLeod DG:
Urology 51:158-60, 1998. |
13.
p53 protein and gene alterations in pathological stage
C prostate carcinoma (letter).
Moul JW, Bauer JJ, Sesterhenn IA, Stackhouse GB, Srivastava:
J Urol, 159:1648-9, 1998. |
14. Efficacy of multiple administration of a recombinant
adenovirus expressing wild-type p53 in an immune-competent mouse
tumor model.
Li Z, Rakkar A, Katayose Y, Kim M, Shanmugam N, Srivastava S,
Moul JW, McLeod DG, Cowan KH, and Seth P:
Gene Therapy, 5:605-613, 1998. |
15. Prognostic risk factors that identify patients with
clinical stage I nonseminomatous germ cell tumors at low risk
and high risk for metastasis.
Heidenreich A. Sesterhenn IA, Mostofi FK, Moul JW:
Cancer, 83:1002-11, 1998. |
16.
Molecular analysis of p16 (Ink4)/CDKN2 and p15(INK4B)/MTS2
genes in primary human testicular germ cell tumors.
Heidenreich A. Gaddipati JP, Moul JW, Srivastava S:
J Urol, 159:1725-30, 1998. |
17.
Immunohistochemical expression of monoclonal antibody 43-9F
in testicular germ cell tumors.
Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW:
Int. J Androl, 21:283-8, 1998. |
18.
Immunohistochemical and mutational analysis of the p53
tumor suppressor gene and the bcl-2 oncogene in primary testicular
germ cell tumours.
Heidenreich A, Schenkman NS, Sesterhenn IA, Mostofi KF, Moul,
JW, Srivastava S, Engelman, UH:
APMIS (Denmark), 106(1) 90-99, 1998. |
19.
Molecular analysis of p16Ink4/CDKN2 and p15Ink4B/MTS2
Genes in Primary Human Testicular Germ Cell Tumors.
Heidenreich A, Gaddipati JP, Moul JW, and Srivastava S:
J. Urol., 159:1725-1730, 1998. |
20.
A Long-term Study of the Efficacy of Treatment of Localized
Prostate Cancer.
Friedrichs MD, Moul JW, Wojcik B, Donatucci C, Optenberg S,
Kreder K, Thompson IM:
Urol Oncol., 1998. |
 Back
to Top |  Next
Page |
|
